Peptides for Uterine Fibroids: Targeted & Hormonal Approaches

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Uterine fibroids, common benign growths, can be treated with novel peptide therapies. Collagenase peptides (e.g., EN3835) directly break down fibroid collagen, offering a localized, non-hormonal approach. GnRH agonist peptides reduce estrogen to shrink fibroids but carry systemic hormonal side effects. The choice depends on patient needs and fibroid characteristics.

Uterine fibroids, also known as leiomyomas, are benign growths of the uterus that affect a significant number of women, particularly during their reproductive years. These fibroids can cause a range of symptoms including heavy menstrual bleeding, pelvic pain, pressure, and infertility. Current treatments often involve surgical removal or hormonal therapies that can have undesirable side effects. However, novel peptide-based approaches are emerging as less invasive and more targeted alternatives.

Collagenase Peptides: Targeting Fibroid Structure

One promising area of research involves the use of collagenase enzymes, specifically highly purified clostridial collagenase (e.g., EN3835). Uterine fibroids are characterized by an excessive accumulation of extracellular matrix, primarily collagen. By directly injecting collagenase into the fibroid, these peptides can break down the collagen fibers, leading to a reduction in fibroid size and associated symptoms. A Phase I clinical trial (NCT02889848) demonstrated the safety and tolerability of a single injection of EN3835 into uterine fibroids, with Masson's trichrome stains revealing a 39% reduction in collagen within the fibroid tissue (Duke CTSI, 2022). This direct enzymatic action offers a localized treatment that minimizes systemic exposure.

While specific dosing protocols are still being refined in clinical trials, the concept is to deliver the enzyme directly into the fibroid under imaging guidance. This approach contrasts with systemic medications that affect the entire body. The goal is to achieve significant fibroid reduction with minimal impact on surrounding healthy uterine tissue, potentially preserving fertility and avoiding hysterectomy.

GnRH Agonist Peptides: Hormonal Modulation with Nuance

Gonadotropin-releasing hormone (GnRH) agonist peptides have been a cornerstone in the medical management of uterine fibroids for some time. These peptides work by initially stimulating, then desensitizing, the pituitary gland to GnRH, leading to a reduction in estrogen production. Since fibroid growth is often estrogen-dependent, this reduction can shrink fibroids and alleviate symptoms like heavy bleeding. Examples include leuprolide and goserelin, typically administered as monthly or quarterly injections.

However, the efficacy of GnRH agonists comes with a trade-off: the hypoestrogenic state they induce can lead to menopausal symptoms such as hot flashes, vaginal dryness, and bone density loss if used long-term. This nuance is critical; while effective for short-term fibroid reduction (e.g., prior to surgery), their prolonged use is often limited by these side effects. Add-back therapy (low-dose estrogen and progestin) can mitigate some side effects, but it also partially counteracts the fibroid-shrinking effect.

Collagenase Peptides vs. GnRH Agonist Peptides: Targeted Destruction vs. Systemic Suppression

The fundamental difference between collagenase peptides and GnRH agonist peptides lies in their mechanism of action and target. Collagenase peptides offer a direct, localized attack on the structural integrity of the fibroid by breaking down its collagen framework. This approach is mechanical and aims to physically reduce the fibroid's mass. In contrast, GnRH agonist peptides employ a systemic hormonal suppression strategy, reducing the estrogen that fuels fibroid growth. While both can lead to fibroid shrinkage, the collagenase approach is designed to be more precise and avoid the systemic hormonal side effects associated with GnRH agonists.

For women seeking to avoid hormonal manipulation or those who have contraindications to hormonal therapies, collagenase injections present an attractive alternative. Conversely, GnRH agonists might be preferred for women who need rapid, albeit temporary, fibroid shrinkage or who are not candidates for localized injections. The choice between these approaches depends on the individual patient's symptoms, fibroid characteristics, and overall health profile.

Clinical Takeaway

For women with symptomatic uterine fibroids, collagenase peptide injections (e.g., EN3835) represent a promising, non-hormonal, and localized treatment option, particularly for those seeking to avoid systemic side effects or preserve fertility. While still in early clinical development, initial data shows a significant reduction in fibroid collagen. GnRH agonist peptides remain a viable option for short-term fibroid reduction, especially before surgical intervention, but clinicians must carefully weigh their benefits against the potential for hypoestrogenic side effects. A thorough discussion of these targeted and systemic approaches, considering individual patient needs and preferences, is crucial for optimal management of uterine fibroids.